Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Is Growing Rapidly

Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market


Hepatitis B is a viral infection caused due to transmission of the virus through contact with the blood or other body fluids of an infected person. It is considered as a serious occupational hazard for healthcare professionals, which affects the liver, causing acute and chronic diseases. Hence, hamster ovary cell (CHO) hepatitis B vaccine is considered to be the safe and effective method to prevent the hepatitis B infection.

Drivers & Restraints

The global market is anticipated to rise at a considerable rate during the forecast period. In the recent years, the market was growing at a steady rate and with the rising adoption of strategies by key players; the market is expected to rise over the projected horizon. The major factor that fuels the growth of the market is increase in prevalence of hepatitis B infection worldwide. For example, approximately 887,000 deaths due to hepatitis B infection were recorded in 2015 across the globe.

Sample Link Here:



Product Type-

Pediatric Hepatitis B (CHO) Vaccine

Adult Hepatitis B (CHO) Vaccine






Regional Analysis

The market has been segment into North America, South America, Europe, Asia-Pacific, and Middle East and Africa. Increase in government focus to promote (CHO) hepatitis B vaccination for adults and extensive research carried out for the same are expected to offer lucrative opportunities for the market in North America.

Purchase Link Here:



Merck & Co., Inc.

GlaxoSmithKline Plc

Pfizer Inc.

Sanofi Pasteur

CSL Limited

Emergent Biosolutions

Serum Institute of India

Johnson & Johnson